Viemed Healthcare (VMD) Investor presentation summary

Business overview and growth drivers

• National leader in home-based clinical care, serving over 172,000 patients across all 50 states with a capex-light model and no net debt.

• Core platform built on complex respiratory services, now expanded to sleep, oxygen, airway clearance, and maternal health.

• High-touch, tech-enabled care model reduces costs, increases patient satisfaction, and lowers rehospitalizations.

• Experienced management team with over 80 years of public company experience and more than 20% insider ownership.

• Multiple catalysts include underserved markets, regulatory tailwinds, and a proven growth platform with diversified services.

Market opportunity and clinical impact

• Estimated 25 million people in the U.S. have COPD, with only 6% market penetration for non-invasive ventilation (NIV) therapy.

• Third largest provider in the market, with 14% share among top 10 providers.

• Proprietary clinical platform and 24/7 respiratory therapist support enhance patient engagement and outcomes.

• Real-world studies show significant reductions in mortality, hospital readmissions, ER visits, and healthcare costs for home-based NIV.

Operating model and service diversification

• Lean, mobile workforce with minimal brick-and-mortar presence enables rapid expansion and higher margins.

• Product offerings include ventilation, airway clearance, oxygen concentrators, PAP therapy, and maternal health products.

• Revenue mix has diversified from 87% ventilation in 2019 to 48% in Q4 2025, with growth in sleep, oxygen, maternal, and staffing services.

• Sleep therapy and resupply patient counts grew 62% and 49% YoY, respectively, in 2025.